ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

Epilepsy and Seizure

Lennox-Gastaut Syndrome: Cannabidiol Treatment

What was the impact of add-on cannabidiol treatment in patients aged 2-55 years experiencing drop seizures?

 

© i3alda/Shutterstock.com

Epilepsy and Seizure

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

A study tested four different efficacy criteria for comparing intravenous antiepileptic drugs (AEDs) used to end status epilepticus.

The first study of its kind in Australia examined influenza-associated neurological disease in hospitalized children.

The new SUDEP guidelines, co-developed by the AAN & AES and presented this week at the AAN Annual Meeting, provide clarity to health professionals.

What was the impact of add-on cannabidiol treatment in patients aged 2-55 years experiencing drop seizures?

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

Experimental data suggesting benefits of cannabinoid comes from purified, standardized preparations that may not translate to real world practice.

Pages

Subscribe to Epilepsy and Seizure on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.